Open Payments

BARBARA A BLODI

Type
Physician · Allopathic & Osteopathic Physicians / Ophthalmology
Where
DUBUQUE, IA
NPI
1548236839
Received
$11,028 in 4 records, 2019 to 2025 ($72 general, $10,956 research)
As principal investigator
$2,124,792 of research payments to others in 70 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025Research payment1$421
2024General payment1$13
2022Research payment1$10,535
2019General payment1$58

By company

CompanyRecordsAmountYears
F. Hoffmann-La Roche AG2$10,9562022–2025
Genentech, Inc.1$582019
E.R. Squibb & Sons, L.L.C.1$132024

By nature of payment

NatureRecordsAmount
Research payment2$10,956
Food and Beverage2$72

Records

DateCompanyAmountNatureFormProductStudyYear
2025-07-29F. Hoffmann-La Roche AG$421Research paymentIn-kind items and servicesVabysmo Drug, Immunology and OphthalmologyComparison of Diabetic Retinopathy Progression With 7 Field and Ultrawide Imaging in the Phase 3 YOSEMITE/RHINE Studies2025
2024-11-06E.R. Squibb & Sons, L.L.C.$13Food and BeverageCash or cash equivalentELIQUIS Drug, Cardiovascular2024
2022-09-30F. Hoffmann-La Roche AG$10,535Research paymentIn-kind items and servicesLucentis Biological, OphthalmologyA PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM INJECTION-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF RHUFA2022
2019-10-11Genentech, Inc.$58Food and BeverageIn-kind items and servicesNon-Covered Product Drug, None2019

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-31KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$96,735A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-12-11KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$55,146A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-12-11KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$71,220A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-11-27KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$48,341A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-11-27KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$31,710A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-30KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$32,955A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-17KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$44,785A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-09-18KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$29,986A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-09-11KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$45,835A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-08-21KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$34,574A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-08-07KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$46,740A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-06-25KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$64,006A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-06-25KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$50,890A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-05-26KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$66,334A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-05-26KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$60,955A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-05-16KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$40,785A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-05-16KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$41,105A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-04-28KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$56,261A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-04-28KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$54,875A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-04-17KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$54,175A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-04-09KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$72,078A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-03-12KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$79,101A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-02-27KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$66,615A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-02-21KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$62,656A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-01-20KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$52,175A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-01-08KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$58,836A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2024-12-06KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$45,763A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-11-27KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$49,175A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-11-14KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$47,142A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-10-28KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$40,085A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-10-07KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$48,437A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-09-20KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$36,420A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-09-04KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$33,490A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-08-29KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$7,521A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-08-20KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$27,180A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-08-14KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$26,370A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-07-11KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$32,532A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-07-01KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$21,995A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-06-24KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$37,368A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-06-05KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$13,625A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-05-10KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$33,405A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-05-08KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$9,545A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-04-08KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$36,662A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-04-03KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$5,215A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-03-06KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$17,801A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-03-06KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$2,087A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-02-21KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$20,801A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-02-21KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$7,750A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-01-24KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$33,810A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2024-01-03KYOWA KIRIN, INC.UNIVERSITY OF WISONSIN MADISON$7,521A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a 2024
2023-07-13Genentech, Inc.DEPARTMENT OF OPHTHALMOLOGY AND VISUAL SCIENCES$2,481Phase 2 of RO7171009 in GA2023
2023-05-11Genentech, Inc.DEPARTMENT OF OPHTHALMOLOGY AND VISUAL SCIENCES$1,677Phase 2 of RO7171009 in GA2023
2023-05-11Genentech, Inc.DEPARTMENT OF OPHTHALMOLOGY AND VISUAL SCIENCES$719Phase 2 of RO7171009 in GA2023
2023-04-13Genentech, Inc.DEPARTMENT OF OPHTHALMOLOGY AND VISUAL SCIENCES$1,849Ph 2 Open label extension of aHtra1 in GA2023
2022-10-25Genentech, Inc.DEPARTMENT OF OPHTHALMOLOGY AND VISUAL SCIENCES$5,292PHASE 2 OF RO7171009 IN GA2022
2022-10-18Genentech, Inc.DEPARTMENT OF OPHTHALMOLOGY AND VISUAL SCIENCES$7,831PH 2 OPEN LABEL EXTENSION OF AHTRA1 IN GA2022
2022-10-04Genentech, Inc.DEPARTMENT OF OPHTHALMOLOGY AND VISUAL SCIENCES$512PH 2 OPEN LABEL EXTENSION OF AHTRA1 IN GA2022
2022-05-17Genentech, Inc.DEPARTMENT OF OPHTHALMOLOGY$2,204PH 2 OPEN LABEL EXTENSION OF AHTRA1 IN GA2022
2022-02-15Genentech, Inc.DEPARTMENT OF OPHTHALMOLOGY AND VISUAL SCIENCES$2,204PH 2 OPEN LABEL EXTENSION OF AHTRA1 IN GA2022
2022-01-18Genentech, Inc.DEPARTMENT OF OPHTHALMOLOGY AND VISUAL SCIENCES$4,401PH 2 OPEN LABEL EXTENSION OF AHTRA1 IN GA2022
2021-12-07Genentech, Inc.DEPARTMENT OF OPHTHALMOLOGY AND VISUAL SCIENCES$6,900PH 2 OPEN LABEL EXTENSION OF AHTRA1 IN GA2021
2021-12-02Genentech, Inc.DEPARTMENT OF OPHTHALMOLOGY AND VISUAL SCIENCES$640PH 2 OPEN LABEL EXTENSION OF AHTRA1 IN GA2021
2021-12-02Genentech, Inc.DEPARTMENT OF OPHTHALMOLOGY AND VISUAL SCIENCES$2,560PH 2 OPEN LABEL EXTENSION OF AHTRA1 IN GA2021
2021-09-23Genentech, Inc.DEPARTMENT OF OPHTHALMOLOGY AND VISUAL SCIENCES$2,775PHASE 2 OF RO7171009 IN GA2021
2020-12-15Genentech, Inc.DEPARTMENT OF OPHTHALMOLOGY AND VISUAL SCIENCES$6,626PHASE 2 OF RO7171009 IN GA2020
2020-04-14Genentech, Inc.UNIVERSITY OF WISCONSIN AND VISUAL SCIENCES$6,101PHASE 2 OF RO7171009 IN GA2020
2019-10-24Genentech, Inc.University Of Wisconsin$5,842PHASE 2 OF RO7171009 IN GA2019
2019-10-24Genentech, Inc.University Of Wisconsin$400PHASE 2 OF RO7171009 IN GA2019
2019-10-24Genentech, Inc.University Of Wisconsin$640PHASE 2 OF RO7171009 IN GA2019
2019-10-24Genentech, Inc.University Of Wisconsin$2,560PHASE 2 OF RO7171009 IN GA2019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Dubuque CountyDubuque city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Dubuque, IA, county Dubuque County, IA, state Iowa; placed by its city name.

MeasurePlace (city or town)
Dubuque, IA
County
Dubuque County, IA
State
Iowa
Population B0100359,17499,0303,210,507
Population, 2020 census P159,66799,2663,190,369
Median age B0100238.139.138.6
Under 18 B0100119.9%22.5%22.9%
65 and over B0100120.7%19.3%18.1%
Households B1100126,13140,9891,315,707
Foreign born B050023.9%3.3%5.9%
Median household income B19013$65,845$77,630$75,059
Median family income B19113$89,443$101,913$97,491
Per capita income B19301$38,244$41,404$40,877
Poverty rate B1700112.7%9.7%11.1%
Unemployment rate B230254.5%3.7%3.6%
Civilian labor force B2302531,66753,1311,699,994
Mean commute (minutes) B0801314.616.719.8
Bachelor's degree or higher B1500334.0%33.4%31.4%
Housing units B2500127,83243,2881,437,699
Owner-occupied B2500365.8%73.3%71.7%
Renters B2500334.2%26.7%28.3%
Median home value B25077$204,800$237,300$208,000
Median gross rent B25064$948$959$972
White, not Hispanic B0300285.3%88.3%82.3%
Black B030024.1%2.9%3.8%
Hispanic or Latino B030023.0%3.3%7.3%
Asian B030021.5%1.3%2.5%
American Indian and Alaska Native B030020.0%0.0%0.2%

Economy now FRED unemployment 3.2% in Sep 2026 (3.4% a year earlier); per capita personal income $67,321 in 2025, up 28% in five years (+2.8% after inflation); Unemployment rate: 3.6% in Sep 2016 to 3.2% in Sep 2026; low 2.5%, high 11.0% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Dubuque, IA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.